Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Institut Paoli-Calmettes
- Target Recruit Count
- 57
- Registration Number
- NCT05986071
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT05966584
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
- Conditions
- Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Carrick Therapeutics Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05963984
- Locations
- 🇺🇸
Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida, United States
🇺🇸Mfsmc-Hjwci, Baltimore, Maryland, United States
🇺🇸Saint Luke's Cancer Institute, Kansas City, Missouri, United States
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 135
- Registration Number
- NCT05933395
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05870579
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCCNE1 AmplificationEpithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerEndometrial CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT05867251
- Locations
- 🇺🇸
Texas Oncology - DFW, Dallas, Texas, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Korea University Guro Hospital
- Target Recruit Count
- 202
- Registration Number
- NCT05816655
- Locations
- 🇰🇷
St Mary Hospital, Seoul, Korea, Republic of
🇰🇷Korea university Guro hospital, Seoul, Korea, Republic of
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 30
- Registration Number
- NCT05806671
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
- Conditions
- HER2 Low Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05792410
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Conditions
- Breast CancerGynecologic CancerHNSCCSolid Tumors, Adult
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Scorpion Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05768139
- Locations
- 🇪🇸
START Barcelona_HM Nou Delfos, Barcelona, Spain
🇪🇸Instituto de Investigacion Oncologica Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.